Two brothers with mild congenital erythropoietic porphyria due to a novel genotype

被引:10
作者
Berry, AA
Desnick, RJ
Astrin, KH
Shabbeer, J
Lucky, AW
Lim, HW
机构
[1] Henry Ford Med Ctr, Dept Dermatol, Detroit, MI 48202 USA
[2] NYU, Mt Sinai Sch Med, Dept Human Genet, New York, NY USA
[3] Cincinnati Childrens Hosp, Cincinnati, OH USA
关键词
D O I
10.1001/archderm.141.12.1575
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disease caused by the deficient activity of the heme biosynthetic enzyme, uroporphyrinogen III synthase (URO-synthase), and the accumulation of the nonphysiologic and phototoxic porphyrin I isomers. Clinical manifestations range from severe mutilation to mild erosions and blisters on sun-exposed areas. Evaluation of the URO-synthase mutation and residual enzyme activity has been correlated with the phenotypic expression of the disease. Observations: We describe 16- and 4-year-old brothers with CEP with a mild phenotype due to a novel genotype, one allele having a promoter mutation (-76G -> A) and the other having an exonic missense mutation (G225S). The father and a 4-year-old fraternal twin brother were carriers of the -76G -> A mutation, whereas the mother and a 15-year-old brother were carriers of the G225S mutation. Previous in vitro expression studies demonstrated that the G225S mutation severely decreased URO-synthase activity to 1.2% of normal, whereas the promoter mutation decreased the activity to approximately 50% of wild type, accounting for the mild clinical phenotype. Conclusion: The mild disease phenotype in these patients is a further example of the clinical heterogeneity seen in CEP and is additional proof that in vitro enzyme expression studies provide dependable genotypephenotype correlations.
引用
收藏
页码:1575 / 1579
页数:5
相关论文
共 24 条
[1]  
Anderson KE, 2001, MOL METABOLIC BASES, P2961
[2]   REGIONAL ASSIGNMENT OF THE HUMAN UROPORPHYRINOGEN-III SYNTHASE (UROS) GENE TO CHROMOSOME 10Q25.2-]Q26.3 [J].
ASTRIN, KH ;
WARNER, CA ;
YOO, HW ;
GOODFELLOW, PJ ;
TSAI, SF ;
DESNICK, RJ .
HUMAN GENETICS, 1991, 87 (01) :18-22
[3]   Molecular genetics of congenital erythropoietic porphyria [J].
Desnick, RJ ;
Glass, IA ;
Xu, WM ;
Solis, C ;
Astrin, KH .
SEMINARS IN LIVER DISEASE, 1998, 18 (01) :77-84
[4]   Congenital erythropoietic porphyria: Advances in pathogenesis and treatment [J].
Dsnick, RJ ;
Astrin, KH .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :779-795
[5]  
Fontanellas A, 1996, EUR J HUM GENET, V4, P274
[6]   Congenital erythropoietic porphyria [J].
Fritsch, C ;
Bolsen, K ;
Ruzicka, T ;
Goerz, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (04) :594-610
[7]   Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells [J].
Géronimi, F ;
Richard, E ;
Lamrissi-Garcia, I ;
Lalanne, M ;
Ged, C ;
Redonnet-Vernhet, I ;
Moreau-Gaudry, F ;
de Verneuil, H .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (05) :310-320
[8]   HYDROXYUREA IN CONGENITAL ERYTHROPOIETIC PORPHYRIA [J].
GUARINI, L ;
PIOMELLI, S ;
POHFITZPATRICK, MB .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (15) :1091-1092
[9]   Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation [J].
Harada, FA ;
Shwayder, TA ;
Desnick, RJ ;
Lim, HW .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (02) :279-282
[10]   Congenital erythropoietic porphyria: Prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells [J].
Kauppinen, R ;
Glass, IA ;
Aizencang, G ;
Astrin, KH ;
Atweh, GF ;
Desnick, RJ .
MOLECULAR GENETICS AND METABOLISM, 1998, 65 (01) :10-17